Short Interest in Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Expands By 30.3%
Short Interest in Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX) Expands By 30.3%
Innovation Pharmaceuticals Inc. (OTCMKTS:IPIX – Get Rating) was the target of a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 620,700 shares, an increase of 30.3% from the March 15th total of 476,200 shares. Based on an average daily volume of 738,300 shares, the short-interest ratio is presently 0.8 days.
创新制药公司(OTCMKTS: IPIX — 获取评级)是3月份空头利息大幅增加的目标。截至3月31日,空头利息总额为62.07万股,较3月15日的476,200股增加了30.3%。根据738,300股的平均每日交易量,目前的空头利率为0.8天。
Innovation Pharmaceuticals Stock Down 10.0 %
创新制药股下跌10.0%
Shares of OTCMKTS:IPIX traded down $0.00 during midday trading on Wednesday, hitting $0.02. The stock had a trading volume of 203,046 shares, compared to its average volume of 546,743. The stock has a 50 day moving average price of $0.02 and a two-hundred day moving average price of $0.02. Innovation Pharmaceuticals has a 1 year low of $0.01 and a 1 year high of $0.06.
周三午盘交易中,OTCMKTS: IPIX的股价下跌了0.00美元,触及0.02美元。该股的交易量为203,046股,而平均成交量为546,743股。该股的50天移动平均价格为0.02美元,200天移动平均线价格为0.02美元。创新制药的1年低点为0.01美元,为1年高点0.06美元。
About Innovation Pharmaceuticals
关于创新制药
(Get Rating)
(获取评级)
Innovation Pharmaceuticals, Inc is a clinical stage biotechnology company. It engages in developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The firm's lead cancer compound, Kevetrin, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers.
创新制药公司是一家临床阶段的生物技术公司。它致力于开发具有抗感染、肿瘤、抗炎和皮肤病学应用的疗法。该公司的主要癌症化合物Kevetrin是一种抗癌药物,已在临床前研究中证明了调节p53途径和攻击癌症的能力。
Read More
阅读更多
- Get a free copy of the StockNews.com research report on Innovation Pharmaceuticals (IPIX)
- ASML Reports Massive Growth, Management Points To Sluggish 2023
- Will Analyst Boost Send Lockheed Martin Shares Up, Up and Away?
- Mullen Automotive: Is The Bloom Off The Rose?
- Diversified Abbott Laboratories Could Reverse And Move Higher
- Okta Reversal In Progress While Catalysts Approach
- 免费获取 StockNews.com 关于创新制药 (IPIX) 的研究报告的副本
- ASML报告了大规模增长,管理层指出2023年表现疲软
- 分析师 Boost 会让洛克希德·马丁公司的股价上涨、上涨和下跌吗?
- Mullen Automotive:是玫瑰花的吗?
- 多元化的雅培实验室可能会逆转并走高
- 催化剂接近时Okta的逆转正在进行中
Receive News & Ratings for Innovation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接收创新制药日报的新闻和收视率 -在下面输入您的电子邮件地址,即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Innovation Pharmicals及相关公司最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。